Psychedelic treatments are on the verge of FDA approval. Why Texas is pushing for them, and how Texans could gain access
The FDA is fast-tracking psychedelic treatments, including psilocybin and methylone, for mental health conditions like depression and PTSD. Texas is pushing to create access to these treatments, which have shown promise in clinical trials.
The US FDA is accelerating the approval process for psychedelic treatments, granting National Priority Vouchers to three companies. The treatments include psilocybin compounds for depression and methylone for PTSD. President Donald Trump signed an executive order supporting states, including Texas, in creating access to these therapies. Psilocybin, MDMA, and other psychedelics are being studied in clinical trials for mental health conditions. Researchers believe psychedelics promote healing by inducing the brain's ability to change and form new neural connections. Over 49,000 Americans died by suicide in 2023, and many have sought psychedelic-assisted therapies abroad after unsuccessful treatment in the US.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.